多囊卵巢综合征不孕症患者体外受精-胚胎移植助孕未妊娠的影响因素分析
纪诚 , 苗盛 , 张颖 , 董兆卉 , 王俊容 , 冉征
中国现代医学杂志 ›› 2026, Vol. 36 ›› Issue (17) : 75 -81.
多囊卵巢综合征不孕症患者体外受精-胚胎移植助孕未妊娠的影响因素分析
Analysis of influencing factors of IVF-ET assisted pregnancy in PCOS infertile patients
目的 分析多囊卵巢综合征(PCOS)不孕症患者体外受精-胚胎移植(IVF-ET)助孕未妊娠的影响因素,并根据影响因素构建预测模型。 方法 选取2023年1月—2024年8月吉林大学中日联谊医院生殖医学中心PCOS不孕症患者135例,均进行首次IVF-ET助孕周期并接受新鲜胚胎移植,根据妊娠结果分为未妊娠组和妊娠组。采用多因素一般Logistic回归分析及森林图筛选PCOS不孕症患者IVF-ET助孕未妊娠的影响因素,建立预测模型。绘制受试者工作特征(ROC)曲线分析预测模型对PCOS不孕症患者IVF-ET助孕未妊娠的评估价值,绘制校准曲线进行一致性验证。 结果 135例PCOS不孕症患者中IVF-ET助孕未妊娠发生率为45.93%(62/135)。未妊娠组年龄、体质量指数(BMI)>24 kg/m²占比、胰岛素抵抗指数(HOMA-IR)、基础黄体生成素/卵泡刺激素(LH/FSH)水平均高于妊娠组,基础雌二醇(E2)水平、基础抗苗勒管激素(AMH)水平均低于妊娠组(P <0.05)。多因素一般Logistic回归分析结果显示:孕妇年龄大[O^R =2.955(95% CI:1.573,5.553)]、BMI高[O^R =2.549(95% CI:1.044,6.226)]、HOMA-IR水平高[O^R =2.195(95% CI:1.435,3.355)]、基础LH/FSH水平高[O^R =2.732(95% CI:1.099,6.793)]均是PCOS不孕症患者IVF-ET助孕未妊娠的独立危险因素(P <0.05);基础E2水平高[O^R =0.650(95% CI:0.537,0.786)]、基础AMH水平高[O^R =0.223(95% CI:0.104,0.479)]均是PCOS不孕症患者IVF-ET助孕未妊娠的保护因素(P <0.05)。ROC曲线分析结果显示:年龄、BMI、HOMA-IR、基础E2、基础LH/FSH、基础AMH联合评估PCOS不孕症患者IVF-ET助孕未妊娠的诊断效能更高,AUC值为0.947(95% CI:0.895,0.978),敏感性为90.32%(95% CI:0.804,0.956),特异性为91.78%(95% CI:0.831,0.963)。校准曲线显示预测概率与实际观测概率吻合良好(Brier得分0.087,校准斜率0.894)。内部验证(Bootstrap法及十折交叉验证)提示模型具有较好的稳定性,过拟合风险较低。 结论 PCOS不孕症患者IVF-ET助孕未妊娠的影响因素包括孕妇年龄、BMI,HOMA-IR、基础E2、基础LH/FSH、基础AMH,基于以上影响因素构建的预测模型不仅具有较高的预测效能,预测值与实际发生风险的一致性较高。
Objective To analyze the factors associated with non-pregnancy after in vitro fertilization-embryo transfer (IVF-ET) in infertile patients with polycystic ovary syndrome (PCOS), and build a prediction model based on the influencing factorss. Methods A total of 135 PCOS infertile patients from Reproductive Medicine Center of China-Japan Union Hospital from January 2023 to August 2024 were selected. All patients underwent their first IVF-ET cycle with fresh embryo transfer. According to the pregnancy results, they were divided into non-pregnant group and pregnancy group. Multivariate binary Logistic regression analysis and forest map were used to screen the influencing factors of IVF-ET assisted pregnancy in PCOS infertile patients and establish a prediction model. Receiver operating characteristic (ROC) curve was drawn to evaluate the model for predicting non-pregnancy after IVF-ET in infertile patients with PCOS, and the calibration curve was drawn for consistency verification. Results In this study, the incidence of non‑pregnancy after IVF‑ET in 135 PCOS infertility patients was 45.93% (62/135). The non‑pregnancy group had significantly higher maternal age, proportion of BMI >24 kg/m², HOMA‑IR level, and basal LH/FSH level, but lower basal E2 level and basal AMH level compared with the pregnancy group (all P < 0.05). Multivariate logistic regression analysis showed that advanced maternal age [O^R = 2.955 (95% CI: 1.573, 5.553) ], high BMI [O^R = 2.549 (95% CI: 1.044, 6.226) ], high HOMA‑IR level [O^R = 2.195 (95% CI: 1.435, 3.355) ], and high basal LH/FSH level [O^R = 2.732 (95% CI: 1.099, 6.793) ] were independent risk factors for non‑pregnancy after IVF‑ET in PCOS infertility patients (P < 0.05), whereas high basal E2 level [O^R = 0.650 (95% CI: 0.537, 0.786) ] and high basal AMH level [O^R = 0.223 (95% CI: 0.104, 0.479) ] were protective factors (P < 0.05). ROC curve analysis indicated that the combination of age, BMI, HOMA‑IR, basal E2, basal LH/FSH and basal AMH had higher diagnostic efficacy for predicting non‑pregnancy, with an AUC of 0.947 (95% CI: 0.895, 0.978), a sensitivity of 90.32% (95% CI: 0.804, 0.956) and a specificity of 91.78% (95% CI: 0.831, 0.963). The calibration curve showed good agreement between predicted probabilities and observed outcomes (Brier score 0.087, calibration slope 0.894). Internal validation (bootstrap and ten‑fold cross‑validation) indicated good model stability and low risk of overfitting. Conclusion Factors associated with non-pregnancy after IVF-ET in infertile patients with PCOS include maternal age, body mass index, HOMA-IR, basal E2, LH/FSH and AMH. The prediction model constructed based on the above influencing factorss not only has high predictive efficacy, but also has a high consistency between the predicted value and the actual risk.
| [1] |
Han Y X, Wu H, Sun S Y, et al. Effect of high fat diet on disease development of polycystic ovary syndrome and lifestyle intervention strategies[J]. Nutrients, 2023, 15(9): 2230. |
| [2] |
Stachowska A, KicińSka A M, Kotulak-ChrząSzcz A, et al. Usefulness of the sympto-thermal method with standardized cervical mucus assessment (InVivo method) for evaluating the monthly cycle in women with polycystic ovary syndrome (PCOS)[J]. Healthcare (Basel), 2024, 12(11): 1108. |
| [3] |
Matsuyama S, Whiteside S, Li S Y. Implantation and decidualization in PCOS: unraveling the complexities of pregnancy[J]. Int J Mol Sci, 2024, 25(2): 1203. |
| [4] |
蒋莹, 李亚敏, 韩颖. PCOS不孕患者卵泡液中4种氧化应激标志物水平对IVF-ET结局的影响[J]. 生殖医学杂志, 2024, 33(10): 1323-1331. |
| [5] |
中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6. |
| [6] |
陈子江, 刘嘉茵, 黄荷凤, 不孕症诊断指南[J]. 中华妇产科杂志, 2019, 54(8): 505-511. |
| [7] |
中华医学会生殖医学分会第一届实验室学组. 人类体外受精-胚胎移植实验室操作专家共识(2016)[J]. 生殖医学杂志, 2017, 26(1): 1-8. |
| [8] |
Kicińska A M, Stachowska A, Kajdy A, et al. Successful implementation of menstrual cycle biomarkers in the treatment of infertility in polycystic ovary syndrome-case report[J]. Healthcare (Basel), 2023, 11(4): 616. |
| [9] |
Gao Q Y, Ma C, Meng S Y, et al. Exploration of molecular features of PCOS with different androgen levels and immune-related prognostic biomarkers associated with implantation failure[J]. Front Endocrinol (Lausanne), 2022, 13: 946504. |
| [10] |
谢秋月, 赵小凤, 张湘琪, 促卵泡激素与孕卵指数在不同临床表型多囊卵巢综合征不孕患者中的差异及与促排卵结局的关系[J]. 中国妇幼健康研究, 2025, 36(2): 53-62. |
| [11] |
周晓燕, 汤美玲, 马娟, 多囊卵巢综合征患者体外受精-胚胎移植妊娠结局的影响因素及预测[J]. 中国妇产科临床杂志, 2020, 21(4): 370-373. |
| [12] |
习艳霞, 王慧春, 刘慧文. 基于受试者工作特征曲线分析血清抗苗勒管激素预测多囊卵巢综合征不孕女性辅助生殖妊娠结局的价值[J]. 中国妇幼保健, 2021, 36(9): 2089-2092. |
| [13] |
陈冰, 刘智敏, 符先先, 游离睾酮指数及Irisin对多囊卵巢综合征不孕患者体外受精-胚胎移植治疗妊娠结局预测价值分析[J]. 临床军医杂志, 2022, 50(8): 810-813. |
| [14] |
汤小晗, 唐淑丽, 王明磊, 子宫内膜异位症相关性不孕症患者的胚胎质量及IVF/ICSI-ET结局的研究[J]. 中华生殖与避孕杂志, 2024, 44(8): 791-797. |
| [15] |
吴惠梅, 曾彬, 黄千贻, 血清SF、AMH、APN、NF-κB与肥胖型多囊卵巢综合征不孕患者胰岛素抵抗和IVF-ET助孕妊娠结局的关系研究[J]. 现代生物医学进展, 2022, 22(16): 3153-3157. |
| [16] |
陈宏梅, 陈圜圜, 文壹, 游离睾酮指数联合血清GnSAF、SHBG对多囊卵巢综合征不孕患者IVF-ET治疗妊娠结局的预测价值[J]. 现代生物医学进展, 2023, 23(10): 1983-1987. |
| [17] |
Kruszewska J, Laudy-Wiaderny H, Kunicki M. Review of novel potential insulin resistance biomarkers in PCOS patients-the debate is still open[J]. Int J Environ Res Public Health, 2022, 19(4): 2099. |
| [18] |
Luo X, Dong Y H, Zheng H S, et al. CAPN2 correlates with insulin resistance states in PCOS as evidenced by multi-dataset analysis[J]. J Ovarian Res, 2024, 17(1): 79. |
| [19] |
赵冉冉, 孙桂丽. 超重/肥胖型PCOS患者IVF/ICSI-ET妊娠失败危险因素分析及预测列线图构建[J]. 山东医药, 2023, 63(18): 15-20. |
| [20] |
陈霞慧, 赵莹莹, 黄金娃, 血清瘦素、鸢尾素、SHBG、AQP8与PCOS不孕症接受IVF-ET患者激素水平和妊娠结局的关系研究[J]. 现代生物医学进展, 2022, 22(24): 4790-4794. |
| [21] |
Rudnicka E, Kunicki M, Calik-Ksepka A, et al. Anti-Müllerian hormone in pathogenesis, diagnostic and treatment of PCOS[J]. Int J Mol Sci, 2021, 22(22): 12507. |
| [22] |
Keum J, Kim Y J, Choi S K, et al. The correlation between sex hormone-binding globulin and clinical characteristics according to Anti-Müllerian hormone in women with regular menstrual cycles: a prospective study[J]. J Pers Med, 2024, 14(3): 274. |
| [23] |
胥博, 谢文燕, 付秀虹, 多囊卵巢综合征不孕伴胰岛素抵抗患者行IVF/ICSI-ET的临床结局分析[J]. 中华内分泌外科杂志, 2022, 16(1): 93-97. |
| [24] |
戚静宜, 牛吉峰, 张婵, 维生素D联合抗苗勒管激素预测不孕症患者IVF-ET妊娠结局的临床价值[J]. 中国计划生育学杂志, 2023, 31(2): 380-384. |
吉林省科技发展计划项目(YDZJ202401219ZYTS)
/
| 〈 |
|
〉 |